

Resource Summary Report

Generated by [NIF](#) on Apr 18, 2025

SIB Swiss Institute of Bioinformatics

RRID:SCR_012816

Type: Tool

Proper Citation

SIB Swiss Institute of Bioinformatics (RRID:SCR_012816)

Resource Information

URL: <http://www.sib.swiss/>

Proper Citation: SIB Swiss Institute of Bioinformatics (RRID:SCR_012816)

Description: An academic, non-profit foundation recognized of public utility that coordinates research and education in bioinformatics throughout Switzerland and provides high quality bioinformatics services to the national and international research community. * The first and primary SIB mission consists of providing services, i.e. the bioinformatics research infrastructure for life science research. It is carried through in a top-down approach, with objectives set by the SIB Board of Directors and an implementation plan agreed with the concerned groups. Federal funds are almost exclusively used to fulfill this mission. * Within the second mission the SIB plays a federating role, linking the Swiss bioinformatics community and promoting and coordinating research and education. This activity is mainly performed in a bottom-up way with funding from the universities and other partners and from research grants.

Abbreviations: SIB

Synonyms: SIB Swiss Institute of Bioinformatics, Institut Suisse de Bioinformatique

Resource Type: portal, training resource, organization portal, data or information resource

Keywords: bioinformatics, genomics, proteomics, systems biology

Funding:

Resource Name: SIB Swiss Institute of Bioinformatics

Resource ID: SCR_012816

Alternate IDs: nlx_96822

Record Creation Time: 20220129T080312+0000

Record Last Update: 20250417T065421+0000

Ratings and Alerts

No rating or validation information has been found for SIB Swiss Institute of Bioinformatics.

No alerts have been found for SIB Swiss Institute of Bioinformatics.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 42 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#).

Contreras-Puentes N, et al. (2024) Identification of Genes Hub Associated with Triple-Negative Breast Cancer and Cannabidiol Analogs Potential Inhibitory Agents: An In-silico Study. Asian Pacific journal of cancer prevention : APJCP, 25(5), 1649.

, et al. (2024) The SIB Swiss Institute of Bioinformatics Semantic Web of data. Nucleic acids research, 52(D1), D44.

Waterhouse AM, et al. (2024) The structure assessment web server: for proteins, complexes and more. Nucleic acids research, 52(W1), W318.

Taher MA, et al. (2024) Isolation, characterization and pharmacological potentials of methanol extract of Cassia fistula leaves: Evidenced from mice model along with molecular docking analysis. Heliyon, 10(7), e28460.

Han M, et al. (2024) Isocucurbitacin B inhibits glioma growth through PI3K/AKT pathways and increases glioma sensitivity to TMZ by inhibiting hsa-mir-1286a. Cancer drug resistance (Alhambra, Calif.), 7, 16.

Shompa SA, et al. (2024) Phyto-pharmacological evaluation and characterization of the methanolic extract of the Baccaurea motleyana Müll. Arg. seed: promising insights into its therapeutic uses. Frontiers in pharmacology, 15, 1359815.

Taher MA, et al. (2024) Unlocking the medicinal arsenal of *Cissus assamica*: GC-MS/MS, FTIR, and molecular docking insights. *Health science reports*, 7(9), e70091.

Alam S, et al. (2024) Chemico-pharmacological evaluations of the dwarf elephant ear (*Colocasia affinis* Schott) plant metabolites and extracts: health benefits from vegetable source. *Frontiers in pharmacology*, 15, 1428341.

Mozun R, et al. (2024) Paediatric Personalized Research Network Switzerland (SwissPedHealth): a joint paediatric national data stream. *BMJ open*, 14(12), e091884.

Taher MA, et al. (2024) Indian Shot (*Canna Indica* L). Leaves Provide Valuable Insights into the Management of Inflammation and Other Associated Disorders Offering Health Benefits. *Journal of inflammation research*, 17, 10943.

Ruseva N, et al. (2023) Synthesis and DNase I Inhibitory Properties of New Squaramides. *Molecules* (Basel, Switzerland), 28(2).

Al-Massarani SM, et al. (2023) Biomarker Quantification, Spectroscopic, and Molecular Docking Studies of the Active Compounds Isolated from the Edible Plant *Sisymbrium irio* L. *Pharmaceuticals* (Basel, Switzerland), 16(4).

Malak N, et al. (2023) Density Functional Theory Calculations and Molecular Docking Analyses of Flavonoids for Their Possible Application against the Acetylcholinesterase and Triose-Phosphate Isomerase Proteins of *Rhipicephalus microplus*. *Molecules* (Basel, Switzerland), 28(8).

Durairaj J, et al. (2023) Uncovering new families and folds in the natural protein universe. *Nature*, 622(7983), 646.

Angelova VT, et al. (2023) Design, Synthesis, In Silico Studies and In Vitro Evaluation of New Indole- and/or Donepezil-like Hybrids as Multitarget-Directed Agents for Alzheimer's Disease. *Pharmaceuticals* (Basel, Switzerland), 16(9).

Soliman AF, et al. (2023) Design, biological evaluation, and molecular modelling insights of cupressic acid derivatives as promising anti-inflammatory agents. *Journal of enzyme inhibition and medicinal chemistry*, 38(1), 2187327.

Peralta-Moreno MN, et al. (2023) Autochthonous Peruvian Natural Plants as Potential SARS-CoV-2 Mpro Main Protease Inhibitors. *Pharmaceuticals* (Basel, Switzerland), 16(4).

Jin Z, et al. (2022) Identification of core genes associated with the anti-atherosclerotic effects of Salvianolic acid B and immune cell infiltration characteristics using bioinformatics analysis. *BMC complementary medicine and therapies*, 22(1), 190.

Oliveira FA, et al. (2022) Evaluation of antiplasmodial activity in silico and in vitro of N-acylhydrazone derivatives. *BMC chemistry*, 16(1), 50.

Mohan PK, et al. (2021) Pharmaco-chemical profiling of *Desmodium gangeticum* (L.) DC. with special reference to soil chemistry. *Future journal of pharmaceutical sciences*, 7(1), 210.